Everyone knows someone who has fought cancer, almost forty percent of adults in the United States will face a diagnosis of cancer in their lifetime. During 2014 there were approximately fourteen and a half million citizens that had cancer according to the National Cancer Institute. By 2024 that number is expected to increase to over nineteen million. The advances made by Tempus and companies like it make the prognosis better though. Tempus, which Eric Lefkofsky co-cofounded, is leading the way in precision medicine that is data enabled.
Even with the emergence of electronic health records (EHRs) the healthcare industry has not kept up with modern technology. There are holds in the digital technology and collection of data even with the massive amounts of data generated as it is collected there is not a streamlined and effective way to keep the information so that it is used effectively. This is where the impressive goal that Tempus has comes in. The company developed a way to analyze the molecular and clinical data of patients.
The hurdle was affordable and accessible medical and clinical data even though they company could develop analytics software. Tempus also had to overcome the way that information is being collected and stored for cancer patients. It is typically physical notes or progress notes which are difficult to analyze because they are free text fields.
Tempus is making progress at getting all the data from cancer patients records centralized and easily accessible so that the treatments are more effective. Having this data readily available to everyone who treats the cancer patients will make the treatment for effective as it will be easier to see what progress, and side effects where seen from which treatments. There will be genome sequencing combined with the data so that researchers can find better ways to treat cancer and other diseases.
Details Eric: Facebook.com/eplefkofsky/